Pharmaceutical industry behaviour and the trans pacific partnership agreement

New Zealand Medical Journal

Volumn 127, Issue 1389, 2014, Pages 6-12

  Monasterio, Erik ^a   Gleeson, Deborah ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; OLANZAPINE; QUETIAPINE;

COST EFFECTIVENESS ANALYSIS; DECISION MAKING; DRUG INDUSTRY; EDITORIAL; GOVERNMENT; HEALTH CARE POLICY; HUMAN; NEW ZEALAND; ORGANIZATION; OUTCOME ASSESSMENT; PATENT; PHYSICIAN; PROFESSIONAL PRACTICE; PSYCHOSIS; REIMBURSEMENT;

DRUG COSTS; DRUG INDUSTRY; HUMANS; INTELLECTUAL PROPERTY; INTERNATIONAL COOPERATION; NEGOTIATING; NEW ZEALAND;

EID: 84896711554     PISSN: 00288446     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Editorial

References (33)

1. Wyber R, Perry W. The Trans-Pacific Partnership: An Analysis of the Impact on Health in New Zealand. Nyes Institute, 2013. http://www.nyesinstitute.org/reviews/tpp/
2. Gleeson D, Friel S. Emerging threats to public health from regional trade agreements. The Lancet 2013;381(9876):1507-1509.
3. Gleeson D, Lopert R, Reid P. How the Trans Pacific Partnership Agreement could undermine PHARMAC and threaten access to affordable medicines and health equity in New Zealand. Health Policy 2013;112(3):227-233.
4. Trans Pacific Partnership. Intellectual Property Rights Chapter Draft - February 10, 2011. Available from: http://keionline.org/sites/default/files/tpp-10feb2011-us-text-ipr-chapter.pdf
5. Trans Pacific Partnership. Intellectual Property Rights Chapter (Selected Provisions. Leaked Draft Text, September 2011. http://www.citizenstrade.org/ctc/wp-content/uploads/2011/10/TransPacificIP1.pdf
6. Kilic B, Maybarduk P. Dangers for Access to Medicines in the Trans Pacific Partnership Agreement (TPP): Comparative Analysis of the United States' Intellectual Property Proposal and Laws of New Zealand. Public Citizen, 2012. http://www.citizen.org/documents/ComparativeAnalysisTPPandNZ.pdf
7. Trans Pacific Partnership. Intellectual Property Rights Chapter: Consolidated Text. Leaked Draft Text, TPP Negotiations IP Group, 30 August 2013. http://wikileaks.org/tpp/static/pdf/Wikileaks-secret-TPP-treaty-IP-chapter.pdf
8. United States Trade Representative. (2012) Special 301 Report. USTR, Executive Officer of the President of the United States: Washington D.C. http://www.ustr.gov/sites/default/files/2012%20Special%20301%20Report.pdf
9. United States Congress. (2014) Bipartisan Congressional Trade Priorities Act of 2014 Bill http://www.finance.senate.gov/imo/media/doc/TPA%20bill%20text.pdf
10. Trans Pacific Partnership. Transparency Chapter - Annex on Transparency and Procedural Fairness for Healthcare Technologies, 2011. http://www.citizenstrade.org/ctc/wp-content/uploads/2011/10/TransPacificTransparency.pdf
11. Lopert R. Gleeson D. The high price of "free" trade: U.S. trade agreements and access to medicines. Journal of Law, Medicine and Ethics 2013;41(1):199-223.
12. Baker BK. Threat of pharmaceutical-related IP investment rights in the Trans-Pacific Partnership Agreement: an Eli Lilly v. Canada case study. Investment Treaty News, 20 September 2013. http://www.iisd.org/itn/2013/09/20/threat-of-pharmaceutical-related-ip-investment-rights-in-the-trans-pacific-partnership-agreement-an-eli-lilly-v-canada-case-study/
13. Trans Pacific Partnership. (2012) Investment Chapter (Leaked Draft Text). http://www.citizenstrade.org/ctc/wp-content/uploads/2012/06/tppinvestment.pdf
14. Kesselheim AS. Rising Health Care Costs and Life-Cycle Management in the Pharmaceutical Market. PLoS Med 2013;10(6):e1001461. doi:10.1371/journal.pmed.1001461.
15. Doshi P, Dickersin K, Healy D, et al. Restoring invisible and abandoned trials: a call for people to publish the findings. BMJ 2013;346:f2865.
16. Lacasse JR, Leo J. Ghostwriting at elite academic medical centers in the United States. PLoS Med 2010;7(2):e1000230.
17. Gagnon, MA, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Med 2008;5(1):e1.
18. Gotzsche P. Deadly Medicines and Organised Crime: How Big Pharma has Corrupted Healthcare. Radcliffe Publishing, 2013.
19. Kassirer JP. On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health. New York, NY: Oxford University Press, 2004.
20. Angell M. Drug companies & doctors: A story of corruption. The New York Review of Books, 2009;56(1):8-13.
21. Gøtzsche PC. Corporate crime in the pharmaceutical industry is common, serious and repetitive; 2013. www.cochrane.dk/research/corporatecrime
22. Kesselheim AS, Mello MM, Studdert DM. Strategies and practices in off-label marketing of pharmaceuticals: a retrospective analysis of whistleblower complaints. PLoS Med 2011;8(4):e1000431.
23. GlaxoSmithKline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data. The United States Department of Justice http://www.justice.gov/opa/pr/2012/July/12-civ-842.html
24. Parry J. Head of GSK in China is replaced as details of fraud scandal emerge. BMJ (Clinical Research ed.). 2012;347:f4791-f4791.
25. Tanne JH. AstraZeneca pays $520m fine for off-label marketing. BMJ 2010;340:c2380.
26. Radley DC, Finkelstein SN, Stafford RS. Off-label prescribing among office-based physicians. Archives of Internal Medicine 2006;166(9):1021.
27. Monasterio E, McKean A. Off-label use of atypical antipsychotic medications in Canterbury, New Zealand. N Z Med J 2011;124(1336):24-29. http://journal.nzma.org.nz/journal/124-1336/4700/content.pdf
28. Monasterio E, McKean A. Use of quetiapine in child and adolescent populations-Response to letter from Dr Lambe. Australian and New Zealand Journal of Psychiatry 2013;47(11):1084-1085.
29. Anon. Top 20 Global Therapeutic Products 2010, Total audited markets. Available from http://www.imshealth.com Accessed 16 August 2011.
30. Hitchings AW, Baker EH, Khong TK. Making medicines evergreen. BMJ 2012;345;e7941.
31. Kesselheim A S, Murtagh L, Mello MM. "Pay for delay" settlements of disputes over pharmaceutical patents. New England Journal of Medicine 2011;365(15):1439-1445. http://www.nejm.org/doi/full/10.1056/NEJMhle1102235
32. Hawkes N. AstraZeneca takes legal action to delay generic quetiapine in US. BMJ 2012;344:e2099.
33. Vernaz N, Haller G, Girardin F, et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. PLoS Med 2013;10(6):e1001460.